Discontinuing LMWH Post-Operatively in PVD Patients After Gangrene Surgery

Post-Operative LMWH Management

The American College of Chest Physicians recommends resuming LMWH at least 24 hours post-operatively (48-72 hours for high-bleeding-risk procedures) once adequate surgical hemostasis is achieved, and continuing for a minimum of 7-10 days 1, 2
For low-to-moderate bleeding risk procedures, therapeutic-dose LMWH should be resumed at the previous dose within 24 hours after surgery 1, 3, 4
For high bleeding risk procedures, LMWH resumption should be delayed to 48-72 hours post-operatively 1, 4
The key determinant for resuming LMWH is adequate surgical site hemostasis, which should be assessed by evaluating wound drainage characteristics 5

A stepwise approach can be used for high-bleeding-risk procedures, starting with prophylactic-dose LMWH (enoxaparin 40 mg daily or dalteparin 5,000 IU daily) for VTE prophylaxis on days 1-2 post-op, and then resuming therapeutic-dose LMWH once hemostasis is confirmed 6, 7
Therapeutic dosing of LMWH can be achieved with enoxaparin 1 mg/kg twice daily or 1.5 mg/kg once daily, or dalteparin 100 IU/kg twice daily or 200 IU/kg once daily 1, 3, 6

Major bleeding can occur in up to 20% of patients when therapeutic-dose LMWH is given too close to surgery without regard for surgical bleeding risk 3, 4
Full therapeutic-dose LMWH should not be resumed within 24 hours of high-bleeding-risk surgery 1

Wound drainage characteristics should be assessed before each LMWH dose escalation 5
Baseline hemoglobin, platelet count, and creatinine should be checked before resuming LMWH 3, 4

If the patient was on chronic anticoagulation pre-operatively, oral anticoagulant (warfarin or DOAC) should be resumed on post-operative day 0 or 1 at the usual maintenance dose, and LMWH bridging should be continued until INR reaches therapeutic range (≥2.0) if using warfarin 3, 4, 6
For DOACs, therapy can be resumed 24 hours after low-moderate bleeding risk procedures or 48-72 hours after high-bleeding-risk procedures, and LMWH can be discontinued once DOAC is resumed 7

Patients with PVD undergoing gangrene surgery represent a high thrombotic risk population due to underlying vascular disease, surgical manipulation of vessels, and potential for prolonged immobility 8
This population also represents a high bleeding risk due to infected/necrotic tissue with poor healing, potential for extensive debridement, and compromised tissue integrity 3, 5, 8
A careful balance is required, using prophylactic-dose LMWH initially and then escalating to therapeutic dosing only after confirming adequate hemostasis 4, 5, 7